KKR announced it will acquire Integer Holdings in an all-cash transaction valued at $5.7 billion, taking the medical device contract manufacturer private in one of the largest healthcare buyouts of the year. The deal, which includes the assumption of debt, reflects a growing appetite among mega-funds for specialized manufacturing assets in regulated sectors with long-term demand visibility.
Integer manufactures critical components for cardiac rhythm management devices, neuromodulation systems, and portable medical equipment. The company supplies original equipment manufacturers across the cardiovascular and orthopedic device markets, operating 14 manufacturing facilities in the U.S., Europe, and Asia. Integer reported trailing twelve-month revenue of approximately $1.5 billion as of its most recent quarter, with operating margins in the mid-teens. KKR is paying roughly 3.8x revenue, a premium to the 2.9x median for publicly traded medical device suppliers over the past eighteen months.
The transaction matters because it signals private equity's willingness to deploy large checks into regulated manufacturing infrastructure at a time when public markets have compressed valuations across the healthcare supply chain. Integer's customer base includes several top-ten global device makers, and its manufacturing footprint supports products with multi-year regulatory approval cycles. KKR's control position allows for capital deployment into automation, geographic expansion, and adjacency moves without quarterly earnings pressure. The firm has already demonstrated this playbook with its $3.4 billion take-private of PRA Health Sciences in 2021, which it later merged with ICON to create a contract research organization with over $7 billion in annual revenue.
Operators and allocators should watch for KKR's plans around Integer's private-label strategy and whether the firm consolidates additional contract manufacturing assets under the platform. The medical device supply chain has seen 12 bolt-on acquisitions by PE-backed manufacturers in the past 24 months, and Integer's scale positions it as a natural buyer. Expect clarity on financing structure and debt leverage multiples when the deal closes, likely in Q4 2026 pending regulatory clearance. Watch also for how Integer's OEM customers react; long-term supply agreements typically include change-of-control provisions that could trigger renegotiation.
The deal closed at a 27% premium to Integer's 30-day volume-weighted average share price before announcement, and KKR's cost of capital on the equity check sits well below the company's unlevered free cash flow yield at the purchase price.